Prelude Therapeutics Incorporated (PRLD) Financial Statements (2024 and earlier)

Company Profile

Business Address 175 INNOVATION BOULEVARD
WILMINGTON, DE 19805
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
MRQ
12/31/2023
12/31/2022
12/31/2021
12/31/2020
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments232,935,000201,728,000291,233,000218,309,000
Cash and cash equivalents25,291,00030,605,00031,828,000218,309,000
Short-term investments207,644,000171,123,000259,405,000 
Deferred costs    300,000
Other undisclosed current assets2,654,0002,652,0003,882,0002,200,000
Total current assets:235,589,000204,380,000295,115,000220,809,000
Noncurrent Assets
Operating lease, right-of-use asset30,412,0001,792,0001,707,000 
Property, plant and equipment7,325,0004,908,0003,929,0002,480,000
Other undisclosed noncurrent assets4,339,0009,420,0004,347,000301,000
Total noncurrent assets:42,076,00016,120,0009,983,0002,781,000
TOTAL ASSETS:277,665,000220,500,000305,098,000223,590,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities20,348,00019,870,00017,461,00011,375,000
Accounts payable4,580,0006,777,0007,840,0003,920,000
Accrued liabilities15,768,00013,093,0009,621,0007,455,000
Other undisclosed current liabilities1,481,0001,832,0001,740,000 
Total current liabilities:21,829,00021,702,00019,201,00011,375,000
Noncurrent Liabilities
Liabilities, other than long-term debt18,746,0003,361,000 32,000
Other liabilities3,339,0003,361,000 32,000
Operating lease, liability15,407,000   
Total noncurrent liabilities:18,746,0003,361,000 32,000
Total liabilities:40,575,00025,063,00019,201,00011,407,000
Equity
Equity, attributable to parent, including:237,090,000195,437,000285,897,000212,183,000
Additional paid in capital693,252,000531,682,000505,723,000319,605,000
Accumulated other comprehensive income (loss)223,000(1,692,000)(711,000) 
Accumulated deficit(456,390,000)(334,558,000)(219,120,000)(107,426,000)
Other undisclosed equity, attributable to parent5,0005,0005,0004,000
Total equity:237,090,000195,437,000285,897,000212,183,000
TOTAL LIABILITIES AND EQUITY:277,665,000220,500,000305,098,000223,590,000

Income Statement (P&L) (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Operating expenses(132,277,000)(123,540,000)(113,735,000)(58,763,000)
Operating loss:(132,277,000)(123,540,000)(113,735,000)(58,763,000)
Nonoperating income
(Other Nonoperating income)
10,445,0008,102,0002,041,0001,834,000
Loss from continuing operations:(121,832,000)(115,438,000)(111,694,000)(56,929,000)
Loss before gain (loss) on sale of properties:(111,694,000)(56,929,000)
Net loss available to common stockholders, diluted:(121,832,000)(115,438,000)(111,694,000)(56,929,000)

Comprehensive Income (USD)

3/31/2024
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Net loss:(121,832,000)(115,438,000)(111,694,000)(56,929,000)
Comprehensive loss:(121,832,000)(115,438,000)(111,694,000)(56,929,000)
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,915,000(981,000)(711,000) 
Comprehensive loss, net of tax, attributable to parent:(119,917,000)(116,419,000)(112,405,000)(56,929,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: